News

AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school ...
Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...
Sixteen “safer” Ideal GASV emerged as buys for July. Top-ten tickers to buy were: CALM; FSK; MPLX; ET; YRD; ING; MO; VZ; NWBI ...
Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...
Tariffs, and their potential detrimental impacts on vehicle affordability, company profits, global competitiveness, and ...
New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.
Detailed price information for Ares Capital Corp (ARCC-Q) from The Globe and Mail including charting and trades.
These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.
Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...
Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...